Core Viewpoint - The company, Giant Bio (02367.HK), has received a medical device registration certificate from the National Medical Products Administration of China for its recombinant type I α1 collagen and sodium hyaluronate composite solution, marking a significant advancement in its product offerings [1] Group 1: Product Approval - The product is the world's first recombinant collagen and sodium hyaluronate composite solution approved for improving cheek smoothness, indicating a pioneering position in the market [1] - The approval was achieved through a joint review of device and drug assessments, showcasing the company's robust regulatory compliance [1] Group 2: Market Expansion - The successful approval of this product expands the company's product matrix and highlights its ongoing technological research and industrialization capabilities [1] - The company aims to promote the product's market launch and distribution, leveraging a diverse product portfolio, comprehensive channel network, and refined brand management to meet consumer demands in various scenarios [1] - This development is expected to inject new growth momentum into the company's business in the skin rejuvenation sector, reinforcing its leading market position in health and beauty [1]
巨子生物(02367.HK)：重组I型α1亚型胶原蛋白及透明质酸钠复合溶液产品获医疗器械注册证